Pharmacokinetic principles of dose adjustment of mTOR inhibitors in solid organ transplanted patients - Hartinger - 2022 - Journal of Clinical Pharmacy and Therapeutics - Wiley Online Library
Everolimus in de novo kidney transplant recipients participating in the Eurotransplant senior program: Results of a prospective randomized multicenter study (SENATOR) | PLOS ONE
Recommendations for the use of everolimus in de novo kidney transplantation: False beliefs, myths and realities | Nefrología
Recommendations for the use of everolimus in de novo kidney transplantation: False beliefs, myths and realities - ScienceDirect
PDF) Conversion to everolimus in maintenance patients - Current clinical strategies
De Novo Therapy with Everolimus and Low-Dose Calcineurin Inhibitors in Kidney Transplantation | Semantic Scholar
IJMS | Free Full-Text | Effects of NR1I2 and ABCB1 Genetic Polymorphisms on Everolimus Pharmacokinetics in Japanese Renal Transplant Patients
Recommendations of everolimus use in liver transplant | Gastroenterología y Hepatología (English Edition)
IJMS | Free Full-Text | Prediction of Tacrolimus Exposure by CYP3A5 Genotype and Exposure of Co-Administered Everolimus in Japanese Renal Transplant Recipients
Recommendations for the use of everolimus in de novo kidney transplantation: False beliefs, myths and realities - ScienceDirect
Everolimus dose and trough blood levels, and laboratory values for... | Download Scientific Diagram
Everolimus with Reduced Calcineurin Inhibitor Exposure in De Novo Kidney Transplant Recipients: Efficacy and Safety Outcomes from the TRANSFORM Study - ATC Abstracts
Five-Year Outcomes in Kidney Transplant Patients Converted From Cyclosporine to Everolimus: The Randomized ZEUS Study - American Journal of Transplantation
Transplantology | Free Full-Text | Dyslipidemia in Renal Transplant Recipients
Rationale and design of the OPTIMIZE trial: OPen label multicenter randomized trial comparing standard IMmunosuppression with tacrolimus and mycophenolate mofetil with a low exposure tacrolimus regimen In combination with everolimus in de
Everolimus (Certican) in renal transplantation: a review of clinical trial data, current usage, and future directions - ScienceDirect
Article: Conversion from tacrolimus to everolimus with complete and early glucocorticoid withdrawal after kidney transplantation: a randomised trial (full text) - January 2018 - NJM
Long-term Efficacy and Safety of Everolimus Versus Mycopheno... : Transplantation
Use of everolimus in liver transplantation
Tacrolimus, Sirolimus and Everolimus Doses in HIV-Infected Solid-Organ Recipients, Requiring a Cobicistat-Based Antiretroviral Regimen: Report of Three Cases and Review | SpringerLink
![PDF] Introduction of everolimus in kidney transplant recipients at a late posttransplant stage | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/52b7f3e549ab8e70c2079418becddcf9e9535b89/3-Table1-1.png "PDF] Introduction of everolimus in kidney transplant recipients at a late posttransplant stage | Semantic Scholar")
PDF] Introduction of everolimus in kidney transplant recipients at a late posttransplant stage | Semantic Scholar
Frontiers | Low-Dose Everolimus Maintenance Therapy for Renal Angiomyolipoma Associated With Tuberous Sclerosis Complex
De novo or early conversion to everolimus and long-term cancer outcomes in kidney transplant recipients: A trial-based linkage study - American Journal of Transplantation
Study design. Steroid dose will be at least 5 mg prednisolone or... | Download Scientific Diagram
Everolimus with Reduced-Dose Calcineurin Inhibitor versus Mycophenolate with Standard-Dose Calcineurin Inhibitor in De Novo Kidney Transplant Recipients: Renal Function Results from the TRANSFORM Study - ATC Abstracts
